Exploration of Stellate Ganglion Block in Patients With Cerebral Small Vessel Disease
Launched by ZENG CHANGHAO · Jan 18, 2024
Trial Information
Current as of July 12, 2025
Completed
Keywords
ClinConnect Summary
This study is conducted for Exploration of Stellate Ganglion Block in Patients With Cerebral Small Vessel Disease. This is a prospective study conducted on patients with Cerebral Small Vessel Disease, dysphagia and cognitive impairment. They were divided into the comparison group and observation group evenly. All the patients were provided with routine therapy, while the patients in the observation group were given Stellate Ganglion Block. The swallowing function, cognitive function and activities of daily living of the two groups of patients before and after treatment were evaluated by Pen...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age\>18 years.
- • Meeting the diagnostic criteria for cerebral small vessel disease.
- • Dysphagia confirmed by Videofluoroscopic Swallowing Study
- • Mini-Mental State Examination (MMSE)\<27, indicating the existence of cognitive impairment.
- • No history of prior stroke.
- • Stable vital signs.
- Exclusion Criteria:
- • Dysphagia that might be caused by other diseases that might cause dysphagia, such as head and neck tumors, traumatic brain injury, myasthenia gravis, etc.
- • Cognitive impairment that might be caused by other diseases, such as Alzheimer's disease, Parkinson's disease, brain injury, etc.
- • Neurological blockade contraindications such as bleeding tendency, blocked site infection.
- • Unable to successfully finish the assessment of this study.
- • Complicated with severe liver and kidney failure, tumors, or hematological disorders.
- • Simultaneously in need to undergo other therapy that might affect the outcomes of this study.
- • Pregnant or nursing females
About Zeng Changhao
Zeng Changhao is a dedicated clinical trial sponsor focused on advancing medical research and innovation through rigorous and ethically conducted clinical studies. With a commitment to improving patient outcomes, Zeng Changhao collaborates with leading healthcare professionals and research institutions to explore novel therapies and treatment modalities. The organization emphasizes transparency, compliance, and patient safety, ensuring that all trials adhere to the highest regulatory standards. Through its strategic partnerships and a patient-centric approach, Zeng Changhao aims to contribute significantly to the development of effective and safe healthcare solutions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Zhengzhou, Henan, China
Guangzhou, Guangdong, China
Beijing, Beijing, China
Beijing, Beijing, China
Zhengzhou, Henan, China
Zhenzhou, , China
Zhongguo, , China
Zhongguo, , China
Zhongguo, , China
Patients applied
Trial Officials
Nieto Luis, Master
Principal Investigator
Site Coordinator of United Medical Group
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported